Quick Answer
BRAINSTORM CELL THERAPEUTICS INC. reported Stockholders Equity of -$9.98 million for fiscal year 2025.
BRAINSTORM CELL THERAPEUTICS INC. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$9.98M | -28.6% |
| 2024 | -$7.76M | -59.8% |
| 2023 | -$4.86M | -61.1% |
| 2022 | -$3.02M | -115.6% |
| 2021 | $19.34M | -45.5% |
| 2020 | $35.46M | +390.1% |
| 2019 | -$12.22M | -343.7% |
| 2018 | $5.02M | -14.7% |
| 2017 | $5.88M | -40.6% |
| 2016 | $9.90M | -29.9% |
| 2015 | $14.13M | +111.7% |
| 2014 | $6.67M | +143.7% |
| 2013 | $2.74M | -31.2% |
| 2012 | $3.98M | +167.6% |
| 2011 | $1.49M | +424.2% |
| 2010 | -$459.0K | +73.7% |
| 2009 | -$1.74M | +16.0% |
| 2008 | -$2.08M | +14.5% |
| 2007 | -$2.43M | -33.7% |
| 2006 | -$1.82M | +77.0% |
| 2006 | -$7.91M | -1223.7% |
| 2005 | $704.0K | +2371.0% |
| 2004 | -$31.0K | -247.6% |
| 2003 | $21.0K | -60.4% |
| 2002 | $53.0K | -22.1% |
| 2001 | $68.0K | — |
| 2000 | $0.00 | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$7.69M | -27.0% | -27.0% |
| June 30, 2025 | -$6.06M | -71.7% | +18.8% |
| March 31, 2025 | -$7.46M | -34.4% | +4.0% |
| December 31, 2024 | -$7.76M | -59.8% | -28.2% |
| September 30, 2024 | -$6.06M | -134.6% | -71.7% |
| June 30, 2024 | -$3.53M | +9.1% | +36.5% |
| March 31, 2024 | -$5.55M | -14.7% | -14.2% |
| December 31, 2023 | -$4.86M | -61.1% | -88.1% |
- BRAINSTORM CELL THERAPEUTICS INC. showed a decrease of -28.6% in Stockholders Equity compared to the prior fiscal year.
- The most recent figure is from BRAINSTORM CELL THERAPEUTICS INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: